As IDH inhibition reprograms chromatin rather than directly debulking tumor mass, responses are differentiation-led, often unfolding over weeks and accompanied by transient leukocytosis or inflammatory flares manifesting as DS. The gene discussed is IDH2; the disease is Dravet syndrome.